Skip to main content
Clinical Trials/DRKS00016416
DRKS00016416
Recruiting
Not Applicable

Prospective evaluation of detection of circulating tumor DNA (ctDNA) to predict recurrence after definitive therapy of localized stage lung cancer (PREDICT) - PREDICT

Klinik für Kardiologie und Pneumologie, Klinikum Esslingen0 sites180 target enrollmentApril 8, 2019

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
lung cancer nsclc and sclc
Sponsor
Klinik für Kardiologie und Pneumologie, Klinikum Esslingen
Enrollment
180
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
April 8, 2019
End Date
TBD
Last Updated
last year
Study Type
Observational
Sex
All

Investigators

Sponsor
Klinik für Kardiologie und Pneumologie, Klinikum Esslingen

Eligibility Criteria

Inclusion Criteria

  • Patients with NSCLC stage I\-IVA with planned curative therapy. SCLC stage I\-IIIC with planned curative therapy.

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Not specified

Similar Trials